Drug Trial Radar · NCT05434663
Safety Study of Repeat Doses of SUSTOL in Adults
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 13, 2022
Primary completion
Sep 18, 2023
Study completion Sep 18, 2023
Sponsor
- Lead sponsor
- Heron TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a repeat-dose, single-arm, open-label study that evaluated the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy \[MEC\] or Anthracycline and Cyclophosphamide \[AC\] combination regimen).
Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
SUSTOLDrug
SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles. Supplied in commercially available SUSTOL kits.
SUSTOL kit components for administrationDevice
Each SUSTOL kit includes 1 sterile glass syringe containing 10 mg granisetron/0.4 mL, 1 sterile 18 Ga 5/8" special thin-walled administration needle, 2 sodium acetate syringe warming pouches, and 1 Point Lok needle protection device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Severe Subject-reported ISRs With Significant Impact on ADLTime frame: Up to approximately 17 weeks: From the subject's first SUSTOL dose through the final study visit (28 days after the subject's last SUSTOL dose).
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi
Gabrail Cancer Center Research
Canton, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.